Insider Transactions in Q2 2023 at Better Therapeutics, Inc. (BTTX)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2023
|
Elder Granger |
BUY
Open market or private purchase
|
Direct |
600
+27.27%
|
$0
$0.87 P/Share
|
|
Apr 10
2023
|
David P Perry Executive Chairman |
BUY
Open market or private purchase
|
Indirect |
4,969,697
+30.08%
|
$0
$0.82 P/Share
|
|
Apr 10
2023
|
Andrew J. Armanino |
BUY
Open market or private purchase
|
Indirect |
303,030
+40.01%
|
$0
$0.82 P/Share
|
|
Apr 10
2023
|
Geoffrey M. Parker |
BUY
Open market or private purchase
|
Direct |
303,030
+46.9%
|
$0
$0.82 P/Share
|
|
Apr 10
2023
|
Frank Karbe Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
242,424
+45.33%
|
$0
$0.82 P/Share
|
|
Apr 05
2023
|
Mark A. Berman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,450
+23.33%
|
-
|
|
Apr 05
2023
|
Mark Heinen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,000
+27.87%
|
-
|
|
Apr 05
2023
|
Kristin Wynholds Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,450
+33.62%
|
-
|